MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2020.02.004

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2020

Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).

Lazareva Olga V, Turkina Anna G, Chelysheva Ekatarina Yu, Kulikovsky Anton A, Galayko Maria V, Senderova Olga M, Pepeliaeva Valentina M, Meresiy Sergey V, Luchinin Alexandr S, Milutina Galina I, Gavrilova Lyubov V, Avdeeva Lyudmila B, Dasheeva Elena B, Vinogradova Olga Yu, Julhakyan Hunan L, Kulikov Sergey M

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Russia took part in the multicenter population-based study (Europe) and included 6.8% adult patients with newly diagnosed chronic myeloid leukemia (CML). The objective of this study was to analyze the mortality in the Russian cohort of patients with newly diagnosed CML in the EUTOS PBS observational study.

PATIENTS AND

METHODS

The analyzed cohort consisted of 197 patients (>18 years) with Ph+/BCR-ABL1+ CML diagnosed in the period from October 1, 2009 through December 31, 2012 from 6 regions of Russia. The distribution of the phases of CML were: chronic phase (CP), 93.4% and accelerated phase (AP) + blast crisis (BC), 6% + 0.6%. The median age was 50 years (range, 18-82 years); the male/female ratio was equal.

RESULTS

The overall survival (OS) at 5, 6, and 7 years was 80% (95% confidence interval [CI], 72%-86%), 78% (95% CI, 65%-80%), and 73% (95% CI, 65%-80%), respectively (P < .001). The 5-year OS in patients with AP and BC was 39%. In Russia, the study was prolonged, with a median follow-up of 77 months (range, 0.7-108 months): 141 (71.5%) patients were alive, 47 (24%) patients died, and the status of 9 (4.5%) patients is was unknown. Forty-seven (23.8%) patients died during the follow-up period. The largest number of deaths was observed in the first year after the CML diagnosis: 17 (36%) of 47 cases, 3 of 17 died refusing the CML treatment. At the seventh year of CML therapy, 1 patient died after allogenic hematopoietic stem cell transplantation. The causes of death were: (1) progression of CML to AP/BC in 20 (43%) patients; (2) death in remission in 5 (11%) patients with complete cytogenetic response (CCyR) and/or major molecular response; and (3) death without progression to AP/BC but with signs of leukemia in 22 (46%) patients. The 5-year cumulative incidence of death from all reasons was 20%; the cumulative incidence of CML-related and non-CML-related death at the fifth year was 18% and 11%, respectively.

CONCLUSION

In general, the results of treatment in the Russian population sample of non-selected patients with CML were comparable with the data of the total European cohort. The CML-related deaths prevailed in the first year of CML therapy. The appropriate monitoring and therapy interventions during the first year of CML treatment are apparently important for the long-term treatment results.

Для цитирования: Lazareva Olga V, Turkina Anna G, Chelysheva Ekatarina Yu, Kulikovsky Anton A, Galayko Maria V, Senderova Olga M, Pepeliaeva Valentina M, Meresiy Sergey V, Luchinin Alexandr S, Milutina Galina I, Gavrilova Lyubov V, Avdeeva Lyudmila B, Dasheeva Elena B, Vinogradova Olga Yu, Julhakyan Hunan L, Kulikov Sergey M. Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).. Clinical lymphoma, myeloma & leukemia. 2020. DOI: 10.1016/j.clml.2020.02.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.